Outcomes after virological failure to first-line second-generation INSTI-based therapy in a real-life setting

被引：0
|
作者：
Borjesson, R. Papaioannu [1 ]
Clemente, T. [1 ]
Diotallevi, S. [2 ]
Lolatto, R. [2 ]
Forniti, A. [3 ]
Bottanelli, M. [1 ]
Galli, L. [2 ]
Alberton, F. [1 ]
Muccini, C. [2 ]
Hasson, H. [2 ]
Castagna, A. [2 ]
Spagnuolo, V. [2 ]
机构：
[1] Univ Vita Salute San Raffaele, Milan, Italy
[2] Ist Sci San Raffaele, Infect Dis Unit, Milan, Italy
[3] Univ Florence, Azienda Osped Univ Pisana, Infect Dis Unit, Florence, Italy
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
929
引用
收藏
页码：170 / 172
页数：3
相关论文
共 50 条
  • [1] Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting
    Borjesson, Rebecka Papaioannu
    Clemente, Tommaso
    Diotallevi, Sara
    Lolatto, Riccardo
    Forniti, Arianna
    Bottanelli, Martina
    Galli, Laura
    Gianotti, Nicola
    Muccini, Camilla
    Hasson, Hamid
    Castagna, Antonella
    Spagnuolo, Vincenzo
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 80 (02) : 405 - 408
  • [2] FAILURE TO FIRST-LINE DIRECT ANTIVIRAL (DAA) TREATMENT OF HCV INFECTION IN AN ITALIAN REAL-LIFE URBAN SETTING
    Di Paolo, D.
    Rossi, P.
    Lenci, I.
    Milana, M.
    Masetti, C.
    Santopaolo, F.
    Lionetti, R.
    D'Offizi, G.
    Pellicelli, A.
    Fondacaro, L.
    Siciliano, M.
    Tortora, A.
    Chiesara, F.
    Moretti, A.
    Ceccherini-Silberstain, F.
    Cento, V.
    Perno, C. F.
    Angelico, M.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S755 - S755
  • [3] Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort
    Annie Fourrier-Réglat
    Denis Smith
    Magali Rouyer
    Jacques Bénichou
    Rosine Guimbaud
    Yves Bécouarn
    Olivier Bernard
    Pernelle Noize
    Nicholas Moore
    Alain Ravaud
    Targeted Oncology, 2014, 9 : 311 - 319
  • [4] Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort
    Fourrier-Reglat, Annie
    Smith, Denis
    Rouyer, Magali
    Benichou, Jacques
    Guimbaud, Rosine
    Becouarn, Yves
    Bernard, Olivier
    Noize, Pernelle
    Moore, Nicholas
    Ravaud, Alain
    TARGETED ONCOLOGY, 2014, 9 (04) : 311 - 319
  • [5] Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia
    Ward, Kristen
    Citrome, Leslie
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (04) : 399 - 409
  • [6] The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia
    Andrews, Claire N.
    Lipton, Jeffrey
    LANCET HAEMATOLOGY, 2019, 6 (08): : E385 - E386
  • [7] REAL-LIFE DATA ON LEN/DEX COMBINATION AT FIRST-LINE THERAPY OF MULTIPLE MYELOMA
    Leotta, V.
    Romano, A.
    Del Fabro, V.
    Di Giorgio, M.
    Di Raimondo, F.
    Conticello, C.
    HAEMATOLOGICA, 2019, 104 : 69 - 69
  • [8] First-Line Treatment for Patients With CML in Chronic Phase: Second-Generation TKIs Are the Therapy of Choice
    Cortes, Jorge
    ONCOLOGY-NEW YORK, 2013, 27 (08): : 781 - 781
  • [9] Inflammatory biomarkers and soft tissue changes among patients commencing second-line antiretroviral therapy after first-line virological failure
    Mwasakifwa, Gwamaka Eliudi
    Amin, Janaki
    Kelleher, Anthony
    Boyd, Mark A.
    AIDS, 2021, 35 (14) : 2289 - 2298
  • [10] Outcome of older myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting
    d'Epinay, Murielle Lalive
    Guesewell, Sabine
    Graf, Nicole
    Mey, Ulrich J. M.
    Driessen, Christoph
    Hitz, Felicitas
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 716 - 723
12345